公开(公告)号：US20240361301A1

公开(公告)日：2024-10-31

申请号：US18687654

申请日：2022-09-09

Applicant: Flagship Pioneering Innovations VI, LLC

Inventor： Morag Helen STEWART ,  Angeliki CHALKIADAKI ,  Yuge JI ,  Fabian Alexander WOLF ,  Nicholas McCartney PLUGIS ,  Poorya HOSSEINI ,  Inna LIPCHINA ,  Sophie Andrea TRITSCHLER

IPC: G01N33/50 ,  A61K45/06 ,  C12N5/071

CPC classification number: G01N33/5088 ,  A61K45/06 ,  C12N5/0679 ,  G01N33/5023 ,  C12N2503/04 ,  C12N2533/90

Abstract: The present disclosure relates, inter alia, to perturbagens and methods for directing a change in the cell state of an intestinal stem cell and/or a basal cell. It also relates to methods for increasing a quantity of goblet progenitors, goblet cells, Paneth cells, and/or enteroendocrine cells or immediate progenitors thereof and/or the ratios thereof, and methods for decreasing the function and quantity of goblet cells or immediate progenitors thereof. Further, the present disclosure relates to methods for treating diseases or disorders characterized by, at least, abnormal function, abnormal ratios and/or abnormal numbers of goblet progenitors, goblet cells, Paneth cells, and/or enteroendocrine cells, or immediate progenitors thereof.

公开(公告)号：US20200306286A1

公开(公告)日：2020-10-01

申请号：US16772678

申请日：2018-12-14

Applicant: FLAGSHIP PIONEERING INNOVATIONS VI, LLC

Inventor： Morag Helen STEWART ,  Catherine CIFUENTES-ROJAS ,  Ki Young PAEK ,  Avak KAHVEJIAN ,  Nicholas McCartney PLUGIS ,  Alexandra Sophie DE BOER ,  Erica Gabrielle WEINSTEIN ,  Sebastian TROUSIL

IPC: A61K31/7088 ,  C07K7/06 ,  C12P21/00 ,  C12N15/67

Abstract: This invention relates generally to pharmaceutical compositions and preparations of circular polyribonucleotides and uses thereof.

公开(公告)号：US20240374592A1

公开(公告)日：2024-11-14

申请号：US18687684

申请日：2022-09-14

Applicant: Flagship Pioneering Innovations VI, LLC

Inventor： Morag Helen STEWART ,  Mauricio CORTES ,  Fabian Alexander WOLF ,  Nicholas McCartney PLUGIS

IPC: A61K31/506 ,  A61K31/166 ,  A61K31/167 ,  A61K31/18 ,  A61K31/341 ,  A61K31/35 ,  A61K31/365 ,  A61K31/4184 ,  A61K31/496 ,  A61K31/513 ,  A61K31/519 ,  A61K31/535 ,  G01N33/50

Abstract: The present disclosure relates, inter alia, to perturbagens and methods for directing a change or inhibiting a change in the cell state of a hematopoietic progenitor cell. It also relates to methods for increasing or decreasing a quantity of neutrophils, monocytes or immediate progenitors thereof and/or the ratios thereof. Further, the present disclosure relates to methods for treating diseases or disorders characterized by, at least, abnormal ratios of neutrophils to monocytes and/or abnormal numbers thereof.

公开(公告)号：US20210292761A1

公开(公告)日：2021-09-23

申请号：US17262591

申请日：2019-07-24

Applicant: FLAGSHIP PIONEERING INNOVATIONS VI, LLC

Inventor： Avak KAHVEJIAN ,  Nicholas McCartney PLUGIS ,  Alexandra Sophie DE BOER ,  Morag Helen STEWART ,  Catherine CIFUENTES-ROJAS ,  Ki Young PAEK

IPC: C12N15/115 ,  A61K31/7088 ,  A61K31/704 ,  C12N15/113

Abstract: This invention relates generally to pharmaceutical compositions and preparations of circular polyribonucleotides and uses thereof.

公开(公告)号：US20220257794A1

公开(公告)日：2022-08-18

申请号：US17617632

申请日：2020-06-14

Applicant: Flagship Pioneering Innovations VI, LLC

Inventor： Alexandra Sophie DE BOER ,  Erica Gabrielle WEINSTEIN ,  Nicholas McCartney PLUGIS ,  Catherine CIFUENTES-ROJAS ,  Morag Helen STEWART ,  Avak KAHVEJIAN

IPC: A61K48/00 ,  C12N15/85 ,  A61K35/17 ,  C07K14/725 ,  C12N15/90 ,  C12N15/11 ,  C12N9/22 ,  C07K16/28 ,  A61P35/00 ,  C12N15/115

Abstract: This invention relates generally to pharmaceutical compositions and preparations of circular polyribonucleotides and uses thereof in cellular therapy.

公开(公告)号：US20220088049A1

公开(公告)日：2022-03-24

申请号：US17433658

申请日：2020-03-01

Applicant: Flagship Pioneering Innovations VI, LLC

Inventor： Avak KAHVEJIAN ,  Nicholas McCartney PLUGIS ,  Alexandra Sophie DE BOER ,  Ellese Marie CARMONA ,  Morag Helen STEWART ,  Roger Joseph HAJJAR

IPC: A61K31/7088 ,  A61K47/10

Abstract: Disclosed herein are methods and compositions for delivery of a polyribonucleotide. In some cases, the methods and compositions provided herein are suitable for in vivo delivery of polyribonucleotides. In certain aspects, also disclosed herein are pharmaceutical compositions for delivery of polyribonucleotide having biological effects.

公开(公告)号：US20240360411A1

公开(公告)日：2024-10-31

申请号：US18687661

申请日：2022-09-01

Applicant: FLAGSHIP PIONEERING INNOVATIONS VI, LLC

Inventor： Mauricio CORTES ,  Fabian WOLF ,  Nicholas Mccartney PLUGIS ,  Morag Helen STEWART ,  Umut ESER

IPC: C12N5/078 ,  A61K35/18 ,  A61K35/19 ,  A61P7/00

CPC classification number: C12N5/0641 ,  A61K35/18 ,  A61K35/19 ,  A61P7/00 ,  C12N5/0644 ,  C12N2501/999 ,  C12N2503/00 ,  C12N2506/11

Abstract: The present disclosure provides methods for increasing the quantity and/or the ratios of erythroblasts, reticulocytes, and/or erythrocytes, or progenitors thereof, in which any of these cells express HbF (e.g. HbF+ and/or HbFhigh cells); increasing the quantity of erythrocytes and/or the ratios of erythrocytes to other related cells. The present disclosure relates, inter alia, to perturbagens and methods for directing a change in the cell state of a progenitor cell. The present disclosure further provides methods for treating diseases or disorders characterized by, for example, oxygen delivery deficiencies and/or reduced expression and/or activity of hemoglobin; abnormal erythron distribution and/or physiology or an erythrocyte deficiency; and diseases or disorders characterized by, at least, abnormal ratios and/or abnormal numbers of megakaryocytes, proplatelets, and/or platelets or immediate progenitors thereof.

公开(公告)号：US20230077584A1

公开(公告)日：2023-03-16

申请号：US17941632

申请日：2022-09-09

Applicant: Flagship Pioneering Innovations VI, LLC

Inventor： Morag Helen STEWART ,  Angeliki CHALKIADAKI ,  Fabian Alexander WOLF ,  Sophie Andrea TRITSCHLER ,  Nicholas McCartney PLUGIS

IPC: C12N5/071 ,  A61P3/04

Abstract: The present disclosure relates, inter alia, to perturbagens and methods for directing a change in the cell state of an intestinal stem cell. It also relates to methods for increasing a quantity of enteroendocrine cells, goblet progenitors, goblet cells, and/or Paneth cells or immediate progenitors thereof and/or the ratios thereof. Further, the present disclosure relates to methods for treating diseases or disorders characterized by, at least, abnormal function, abnormal ratios and/or abnormal numbers of enteroendocrine cells, goblet progenitors, goblet cells, and/or Paneth cells, or immediate progenitors thereof.

公开(公告)号：US20220142896A1

公开(公告)日：2022-05-12

申请号：US17433655

申请日：2020-03-01

Applicant: Flagship Pioneering Innovations VI, LLC

Inventor： Avak KAHVEJIAN ,  Nicholas McCartney PLUGIS ,  Alexandra Sophie DE BOER ,  Ellese Marie CARMONA ,  Morag Helen STEWART

IPC: A61K8/60 ,  A61Q19/08 ,  A61K8/34 ,  A45D37/00

Abstract: Disclosed herein are methods and compositions for delivery of polyribonucleotide. In some cases, the methods and compositions provided herein are suitable for in vivo delivery of polyribonucleotides. In certain aspects, also disclosed herein are cosmetic compositions for delivery of polyribonucleotide having cosmetic effects.

公开(公告)号：US20210161938A1

公开(公告)日：2021-06-03

申请号：US17173991

申请日：2021-02-11

Applicant: FLAGSHIP PIONEERING INNOVATIONS VI, LLC

Inventor： Morag Helen STEWART ,  Catherine CIFUENTES-ROJAS ,  Ki Young PAEK ,  Avak KAHVEJIAN ,  Nicholas McCartney PLUGIS ,  Alexandra Sophie DE BOER ,  Erica Gabrielle WEINSTEIN ,  Sebastian TROUSIL

IPC: A61K31/7088 ,  C07K7/06 ,  C07K7/00 ,  C12N15/67 ,  C12P21/00

Abstract: This invention relates generally to pharmaceutical compositions and preparations of circular polyribonucleotides and uses thereof.